Ireland's Alkermes Q3 revenue beats on LUMRYZ growth

What happened

Alkermes, an Ireland biopharma firm, reported third-quarter revenue that beat analyst expectations, helped by LUMRYZ sales. Adjusted earnings per share were $0.09. The company did not provide specific guidance in the press release.

Confirmed

Global impact / market context

Revenue above analyst estimates suggests demand for Alkermes treatments, led by LUMRYZ, grew faster than expected. That matters because higher sales can help offset rising operating costs and interest expense, which pulled GAAP net income lower this quarter.

Analyst inference

Analysts rate Alkermes a buy overall, and the median twelve-month price target sits about 27% above its November 2 closing price. Still, the stock traded at 89 times next twelve-month earnings, a rich valuation that leaves little room if growth slows.

Analyst inference

What to watch

1. Watch whether LUMRYZ revenue and the roughly 4,100 patients on therapy keep growing, since LUMRYZ sales were a stated driver of the quarterly revenue beat. Confirmed
2. Monitor whether Alkermes provides specific guidance later, because the company did not give detailed forecasts in the press release, which leaves future revenue uncertain. Proposed
3. Track operating expenses and interest expense, since rising costs cut GAAP net income despite the revenue beat, and watch whether that pressure continues in coming quarters. Analyst inference

Evidence

• Original source link unavailable